When research buyers compare peptide suppliers, one number usually gets the most attention: purity percentage.
We understand why. A high purity number is easy to read, easy to compare, and easy to remember. A product listed at 99% purity naturally looks more reassuring than one with less detail behind it. But in research supply, a purity percentage is only one part of the story.
At Precision Synthetics Canada, we believe a strong Certificate of Analysis should do more than show a large number on a page. It should help researchers understand what was tested, how it was tested, whether the material matches the expected compound, and whether the documentation can be connected to the batch being reviewed.
Purity matters. It just should not be the only thing a buyer looks at.
The Problem With Treating Purity Like the Whole Story
A purity percentage can be useful, but it can also create a false sense of simplicity.
When someone sees a report showing 98%, 99%, or higher, it is easy to assume that the product has been fully verified. In reality, purity is usually answering a narrower question. It tells you how much of the detected sample appears to be the main target compound compared with related impurities under the method used by the lab.
That is important, but it does not automatically answer every other question a researcher should care about.
It does not always confirm that the molecule is the correct identity. It does not prove that the COA belongs to the exact batch being sold. It does not explain whether the report can be verified through the testing laboratory. It does not replace endotoxin screening. It does not guarantee sterility. It does not mean a material is suitable for human or veterinary use.
This is why we think purity should be reviewed as part of a larger documentation picture, not as a standalone marketing claim.
A Simple Way to Think About HPLC Purity
Most peptide purity results are reported using HPLC, which stands for High-Performance Liquid Chromatography.
That sounds complicated, but the basic idea is not hard to understand. Imagine a lab taking a sample and sending it through a specialized testing system that separates the different components in that sample. As those components pass through the machine, the system creates a graph called a chromatogram.
On that graph, the main compound should usually appear as the dominant peak. Smaller peaks may represent related impurities, byproducts, or other detected components. The purity percentage is often calculated by comparing the area of the main peak against the total detected peak area.
In plain English, HPLC helps answer this question:
How much of what the machine detected appears to be the main compound?
That is a valuable question, but it is not the only question.
A strong HPLC result is more useful when the COA also shows the chromatogram, retention time, integration data, test date, lab details, and batch information. Without that context, a purity number by itself is harder to trust.
A COA that only says “99% purity” without showing how the result was reached is not as meaningful as a report that lets the buyer review the actual testing record.
Purity Is Not the Same as Identity
One of the most common misunderstandings around COAs is the difference between purity and identity.
Purity asks how much of the detected sample appears to be the main compound. Identity asks whether the compound appears to be the correct molecule in the first place.
Those are related, but they are not the same.
This is where LC-MS or mass spectrometry becomes important. In simple terms, mass spectrometry helps “weigh” the molecule at a very small scale. If the observed molecular mass lines up with the expected mass of the compound, that supports the identity of the material being tested.
A purity result can look strong, but researchers still need identity-supporting data to better understand whether the material matches the expected peptide.
That is why we do not believe a purity percentage should be treated like a complete verification record. A better COA should help connect purity data with identity-supporting information, batch details, and a clear testing source.
Batch Traceability Matters More Than People Think
Even a strong COA loses value if it cannot be connected to the batch being sold.
This is one of the most important parts of COA review. The product name, lot number, batch identifier, or source record should make sense across the report, product page, and material being reviewed. If the COA is for one batch and the product being sold is from another, the document does not give the buyer the clarity they need.
This is why batch-linked documentation matters.
A real COA should not feel like a floating PDF that could belong to anything. It should be connected to the product or batch in question. It should help the buyer understand where the testing record fits into the larger documentation trail.
At Precision Synthetics Canada, our COA library is built around this principle. We want research buyers to be able to review available batch documentation, compare supporting records, and understand what testing is associated with the product they are considering.
Why We Use More Than One Documentation Layer
There is a difference between having a COA and building a documentation model.
Our current testing model supports source-lab third-party analysis as well as our own separate third-party analysis. The source-lab documentation provides an initial analytical record from the origin side of the supply chain. That gives researchers a starting point for reviewing identity, purity, and batch-related information.
We also support separate third-party verification, including LAL endotoxin screening for supported batches. This gives buyers another review point beyond the original source-lab record.
We believe that matters.
A single purity number can look good, but multiple layers of documentation are more useful for serious review. Source-lab records, independent verification, and endotoxin screening each add a different piece of information. Together, they create a clearer picture than a purity percentage alone.
This does not mean every test answers every question. It means the documentation gives researchers more to review before making a purchasing decision.
What LAL Endotoxin Testing Adds
LAL endotoxin testing is important because it answers a different question than HPLC purity or LC-MS identity testing.
HPLC helps review purity. LC-MS or mass spectrometry helps support identity. LAL endotoxin testing is focused on bacterial endotoxin screening.
That distinction matters. A sample can have a strong purity number and still require separate testing to evaluate other quality-control concerns. Endotoxin testing does not replace purity testing, and purity testing does not replace endotoxin testing. They are different tools for different questions.
For research buyers, LAL endotoxin screening adds another layer of documentation beyond the headline purity percentage. It gives an additional data point to review when evaluating supported batches.
It is also important to be clear about what LAL testing does not mean. It does not make a product sterile. It does not make a product injectable. It does not make a product approved for human or animal use. It is not medical guidance, dosing guidance, or a therapeutic claim.
It is simply another quality-control datapoint that helps researchers review the documentation behind a research material.
Why “99% Pure” Can Still Be a Weak Claim
A high purity claim is only as strong as the documentation behind it.
For example, a 99% purity claim is much more useful when it is supported by a complete COA, a visible chromatogram, identity-supporting data, a batch connection, and a verification pathway. It is much weaker when it appears as a screenshot, a cropped image, a report with no batch link, or a number with no supporting data.
This is where buyers should slow down and look carefully.
Does the report show the compound name clearly? Does the batch or lot number match the product being reviewed? Does the COA show a chromatogram or only a final number? Is there identity-supporting data such as LC-MS or mass spectrometry? Is the lab source visible or verifiable? Is endotoxin screening included where supported? Do the testing date and documentation trail make sense?
These questions are not about making the buying process more complicated. They are about making it more transparent.
A trustworthy supplier should not expect buyers to rely on a purity number alone. The documentation should help explain the claim.
Our View: Better Documentation Builds Better Trust
We know that research buyers want confidence before placing an order. They want to know that the product page is not just polished, but supported. They want to see documentation that is clear, batch-aware, and easy to review.
That is why we put so much emphasis on COA transparency.
Our approach is not built around a single purity percentage. It is built around giving buyers access to more of the documentation trail. That includes source-lab third-party analysis, independent third-party verification, and LAL endotoxin screening where supported.
We also believe that good documentation should be easy to find. Buyers should not have to dig through vague claims or request basic testing records after checkout. The more visible the documentation is before purchase, the easier it is for researchers to make an informed decision.
That is the standard we are working toward.
What Research Buyers Should Look For
When reviewing a peptide COA, the goal is not to find the biggest number. The goal is to understand the full testing picture.
A stronger COA should make the product easier to evaluate. It should connect to a specific batch, show relevant testing data, support the compound identity, include a clear purity result, and provide enough context to understand how the result was produced. Where additional testing is available, such as LAL endotoxin screening, that information should be clearly tied to the documentation set.
A weaker COA usually leaves buyers with more questions than answers. It may show only a final percentage, omit the chromatogram, lack identity support, hide the lab source, mismatch the batch, or provide no way to verify the report.
The best documentation does not ask buyers to “just trust us.” It gives them something they can actually review.
Why This Matters to Precision Synthetics Canada
Precision Synthetics Canada was built for research buyers who care about documentation before checkout.
We know that the research peptide space can be confusing. Many suppliers use similar language. Many products are marketed with similar purity claims. Many buyers are left trying to decide who to trust based on limited information.
We want to make that process clearer.
Our goal is to provide research materials with product details, batch documentation, and supporting analytical records kept visible and accessible. Purity percentage is part of that review, but it is not the whole story. A serious buyer should be able to look beyond the number and review the documentation behind it.
That is why we continue to emphasize COA transparency, independent verification, and LAL endotoxin screening for supported batches.
Because when it comes to research supply, trust should be built on more than a percentage.
Review the Documentation Before You Buy
Before choosing a research peptide supplier, take time to review the available COAs and supporting records. Look beyond the purity percentage. Check whether the report is batch-linked, whether identity is supported, whether the testing source is clear, and whether additional quality-control data is available.
You can review available Precision Synthetics Canada batch documentation through our COA library. For a deeper explanation of common report fields, HPLC chromatograms, LC-MS identity data, LAL endotoxin testing, and fake COA warning signs, visit our guide on how to read a peptide COA.
At the end of the day, a purity number may start the conversation.
The documentation is what earns the trust.
Research-use notice: Precision Synthetics Canada products and documentation are provided strictly for lawful, non-clinical laboratory research purposes only. COAs and testing records are not medical documents, safety guarantees, sterility guarantees, therapeutic endorsements, dosing guidance, or approval for human or veterinary use.